Skip to main content
Erschienen in: International Cancer Conference Journal 4/2020

27.06.2020 | Case report

Prostate-specific antigen (PSA) bounce following salvage radiotherapy to the prostate bed in a patient with prostate cancer post-prostatectomy

verfasst von: Michael Rowe, Ellis Adamson, John McGrane

Erschienen in: International Cancer Conference Journal | Ausgabe 4/2020

Einloggen, um Zugang zu erhalten

Abstract

We present a case of prostate-specific antigen (PSA) bounce in a 76 year old man who underwent salvage radiotherapy to the prostate bed following biochemical relapse 6 years post-radical prostatectomy for a T2N0 Gleason grade 3 + 3 prostate adenocarcinoma; 10 months following completion of salvage radiotherapy for biochemical PSA recurrence of 0.2 μg/L. Following undetectable results (<0.03 μg/L), his PSA rose from 0.04 to 0.3 μg/L with no evidence of prostate cancer recurrence before returning to undetectable levels without medical intervention. This PSA ‘bounce phenomenon’ is well described following radiotherapy to an intact prostate and has been proposed to be the result of a late fibrotic effect on irradiated prostate tissue. To our knowledge, this is the first case published describing the effect in the post-prostatectomy setting. It highlights the importance of serial PSA monitoring to confirm biochemical relapse before committing the patient to androgen deprivation therapy (with its inherent risks and side effects).
Literatur
1.
Zurück zum Zitat Sheinbein C, Teh BS, Mai WY et al (2010) Prostate-specific antigen bounce after intensity-modulated radiotherapy for prostate cancer. Urology 76:728–733CrossRef Sheinbein C, Teh BS, Mai WY et al (2010) Prostate-specific antigen bounce after intensity-modulated radiotherapy for prostate cancer. Urology 76:728–733CrossRef
2.
Zurück zum Zitat Caloglu M, Ciezki JP, Reddy CA et al (2011) PSA bounce and biochemical failure after brachytherapy for prostate cancer: a study of 820 patients with a minimum of 3 years of follow-up. Int J Radiat Oncol Biol Phys 80(3):735–741 Epub 2010 Jun 18CrossRef Caloglu M, Ciezki JP, Reddy CA et al (2011) PSA bounce and biochemical failure after brachytherapy for prostate cancer: a study of 820 patients with a minimum of 3 years of follow-up. Int J Radiat Oncol Biol Phys 80(3):735–741 Epub 2010 Jun 18CrossRef
3.
Zurück zum Zitat Akyol F, Ozyigit G, Selek U et al (2005) PSA bouncing after short term androgen deprivation and 3D-conformal radiotherapy for localized prostate adenocarcinoma and the relationship with the kinetics of testosterone. Eur Urol 48:40–45CrossRef Akyol F, Ozyigit G, Selek U et al (2005) PSA bouncing after short term androgen deprivation and 3D-conformal radiotherapy for localized prostate adenocarcinoma and the relationship with the kinetics of testosterone. Eur Urol 48:40–45CrossRef
4.
Zurück zum Zitat Roy S, Loblaw A, Cheung P et al (2019) Prostate-specific antigen bounce after stereotactic body radiotherapy for prostate cancer: a pooled analysis of four prospective trials. Clin Oncol (R Coll Radiol) 31(9):621–629 Epub 2019 May 21CrossRef Roy S, Loblaw A, Cheung P et al (2019) Prostate-specific antigen bounce after stereotactic body radiotherapy for prostate cancer: a pooled analysis of four prospective trials. Clin Oncol (R Coll Radiol) 31(9):621–629 Epub 2019 May 21CrossRef
5.
Zurück zum Zitat Horwitz EM, Levy LB, Thames HD et al (2006) Biochemical and clinical significance of the posttreatment prostate-specific antigen bounce for prostate cancer patients treated with external beam radiation therapy alone: a multiinstitutional pooled analysis. Cancer 107:1496–1502CrossRef Horwitz EM, Levy LB, Thames HD et al (2006) Biochemical and clinical significance of the posttreatment prostate-specific antigen bounce for prostate cancer patients treated with external beam radiation therapy alone: a multiinstitutional pooled analysis. Cancer 107:1496–1502CrossRef
6.
Zurück zum Zitat Ciezki JP, Reddy CA, Garcia J et al (2006) PSA kinetics after prostate brachytherapy: PSA bounce phenomenon and its implications for PSA doubling time. Int J Radiat Oncol Biol Phys 64(2):512–517 Epub 2005 Oct 6CrossRef Ciezki JP, Reddy CA, Garcia J et al (2006) PSA kinetics after prostate brachytherapy: PSA bounce phenomenon and its implications for PSA doubling time. Int J Radiat Oncol Biol Phys 64(2):512–517 Epub 2005 Oct 6CrossRef
7.
Zurück zum Zitat Naghavi AO, Strom TJ et al (2015) Clinical implications of a prostate-specific antigen bounce after radiation therapy for prostate cancer. Int J Clin Oncol 20(3):598–604CrossRef Naghavi AO, Strom TJ et al (2015) Clinical implications of a prostate-specific antigen bounce after radiation therapy for prostate cancer. Int J Clin Oncol 20(3):598–604CrossRef
8.
Zurück zum Zitat Critz FA, Williams WH, Benton JB et al (2000) Prostate specific antigen bounce after radioactive seed implantation followed by external beam radiation for prostate cancer. J Urol 163(4):1085–1089CrossRef Critz FA, Williams WH, Benton JB et al (2000) Prostate specific antigen bounce after radioactive seed implantation followed by external beam radiation for prostate cancer. J Urol 163(4):1085–1089CrossRef
9.
Zurück zum Zitat Mitchell DM, Swindell R, Elliott T et al (2008) Analysis of prostate-specific antigen bounce after I(125) permanent seed implant for localised prostate cancer. Radiother Oncol 88(1):102–107CrossRef Mitchell DM, Swindell R, Elliott T et al (2008) Analysis of prostate-specific antigen bounce after I(125) permanent seed implant for localised prostate cancer. Radiother Oncol 88(1):102–107CrossRef
10.
Zurück zum Zitat Yamamoto Y, Offord CP, Kimura G et al (2016) Tumour and immune cell dynamics explain the PSA bounce after prostate cancer brachytherapy. Br J Cancer 115(2):195–202CrossRef Yamamoto Y, Offord CP, Kimura G et al (2016) Tumour and immune cell dynamics explain the PSA bounce after prostate cancer brachytherapy. Br J Cancer 115(2):195–202CrossRef
11.
Zurück zum Zitat Romesser PB, Pei X, Shi W et al (2018) Prostate-specific antigen (PSA) bounce after dose-escalated external beam radiation therapy is an independent predictor of psa recurrence, metastasis, and survival in prostate adenocarcinoma patients. Int J Radiat Oncol Biol Phys 100(1):59–67 Epub 2017 Oct 13CrossRef Romesser PB, Pei X, Shi W et al (2018) Prostate-specific antigen (PSA) bounce after dose-escalated external beam radiation therapy is an independent predictor of psa recurrence, metastasis, and survival in prostate adenocarcinoma patients. Int J Radiat Oncol Biol Phys 100(1):59–67 Epub 2017 Oct 13CrossRef
12.
Zurück zum Zitat Agarwal M, Canan T, Glover G et al (2019) Cardiovascular effects of androgen deprivation therapy in prostate cancer. Curr Oncol Rep 21(10):91CrossRef Agarwal M, Canan T, Glover G et al (2019) Cardiovascular effects of androgen deprivation therapy in prostate cancer. Curr Oncol Rep 21(10):91CrossRef
Metadaten
Titel
Prostate-specific antigen (PSA) bounce following salvage radiotherapy to the prostate bed in a patient with prostate cancer post-prostatectomy
verfasst von
Michael Rowe
Ellis Adamson
John McGrane
Publikationsdatum
27.06.2020
Verlag
Springer Singapore
Erschienen in
International Cancer Conference Journal / Ausgabe 4/2020
Elektronische ISSN: 2192-3183
DOI
https://doi.org/10.1007/s13691-020-00428-0

Weitere Artikel der Ausgabe 4/2020

International Cancer Conference Journal 4/2020 Zur Ausgabe

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Blutdrucksenkung könnte Uterusmyome verhindern

Frauen mit unbehandelter oder neu auftretender Hypertonie haben ein deutlich erhöhtes Risiko für Uterusmyome. Eine Therapie mit Antihypertensiva geht hingegen mit einer verringerten Inzidenz der gutartigen Tumoren einher.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.